AIDS Drug Shown to Prevent HIV
in Multinational Trial of HIV-Negative Gay Men
Data Suggests Need for Rectal Gel Option
[via our sister IRMA - International Rectal Microbicide Advocates]
Results of the world’s first efficacy trial of an HIV-prevention approach called oral pre-exposure prophylaxis, or PrEP, were released online in the New England Journal of Medicine today. Data from this trial, called iPrEx, indicated an estimated 43.8% reduction of new HIV infections among men who took an antiretroviral tablet daily to prevent HIV, compared to those who took a placebo pill.[Read the article.]
“This discovery alters the HIV prevention landscape forever. While this level of efficacy is relatively strong, PrEP is not quite ready for prime time and work remains before this strategy is rolled out. However, we are thrilled to have a new prevention option beyond male and female condoms visible on the horizon,” said Jim Pickett, Director of Advocacy at AIDS Foundation of Chicago and Chair of IRMA – International Rectal Microbicide Advocates.
The iPrEx trial evaluated the safety and efficacy of the antiretroviral (ARV) drug TDF/FTC (brand name Truvada) taken once daily for HIV prevention among HIV-negative gay men, transgender women, and other men who have sex with men (MSM).
The participants, 2,499 in all, included individuals from Peru, Ecuador, Brazil, South Africa, Thailand and the United States. Half the men were randomized into the active arm that received Truvada, and the other half were randomized into the placebo arm and received a look-alike pill with no active ingredient. The participants and the researchers did not know who was in either arm.
Enrollment for the trial began in June 2007 and was completed in December 2009. The primary analysis of the results released today includes participants who were followed until May 1, 2010, or for an average of 14 months.
Each participant was tested for HIV at monthly trial visits and given intensive pre-and-post test counseling. Additionally, they were regularly screened for sexually transmitted infections and received condoms, making up a very robust prevention package.
At the end of the trial, there were 36 infections in participants who received Truvada and 64 in recipients who took the placebo. Researchers calculated that the use of Truvada reduced new HIV infections by an estimated 43.8% overall when compared to placebo. While there appeared to be few side effects reported by the men who were taking the Truvada tablet, it is clear that much more information is needed regarding long term safety of this drug.
Other PrEP trials are ongoing. Results from studies among heterosexuals in Africa and injection drug users in Thailand are expected next year.
It is important to emphasize the factors that led to successful use of Truvada to prevent HIV in iPrEx. Taking the pill regularly was one of the most important. Efficacy appeared to be higher among those participants who took the study drugs consistently. Men who did not take the pill regularly did not see a protective benefit. Regular HIV testing and ongoing monitoring by a physician was also critical. For this strategy to work, each of these pieces, including a doctor’s prescription, need to be in place.
“The study team found that about half of the men in the active arm of the trial were in fact not taking their pills regularly, if at all,” said Pickett. “It is not clear why this happened, but it certainly suggests that alternate means of using ARVs to prevent HIV infection may be more acceptable for these men. The primary means of transmission among gay men and other MSM is through unprotected anal intercourse. If we develop an ARV as a gel or lubricant applied rectally – a rectal microbicide – it could be more acceptable for some individuals who don’t like taking pills.”
Many gay men and other MSM already use lubricants for anal intercourse, so they wouldn’t have to modify their behavior to achieve higher levels of protection with a rectal microbicide formulated as a lubricant. Adopting a new behavior—such as taking a pill every day—can be a considerable challenge for some.
Dr. Ian McGowan, one of the principal investigators of the Microbicide Trials Network and Scientific Vice Chair of IRMA agreed. "The data from the iPrEx study are encouraging but the less than ideal adherence rate to oral PrEP clearly show that we need additional prevention approaches such as rectal microbicides that could be used by men and women at risk of HIV infection through unprotected receptive anal intercourse," he said.
The world's third rectal microbicide trial is currently underway with sites in Pittsburgh, Pennsylvania; Boston, Massachusetts; and Birmingham, Alabama. Scientists are testing the rectal safety and acceptability of tenofovir gel, a microbicide developed for vaginal use that has shown promise for preventing HIV through vaginal intercourse. Depending on the outcome of this new study, tenofovir gel could be further evaluated to determine if it can reduce the risk of HIV among both men and women who engage in receptive anal intercourse.
This new Phase I rectal microbicide study, known as MTN-007, aims to determine if rectal use of tenofovir gel is safe, and in particular, does not cause cells in the rectum to become more vulnerable to HIV. Investigators will also ask trial participants questions regarding the gel's desirability. The trial is planning to recruit a total of 60 men and women.
While the rectal microbicide field has gained significant momentum, more focus and resources are needed. In 2010, U.S. $7.2 million is being spent globally on rectal microbicide research. IRMA has calculated that annual investments must increase by 40% from 2011 – 2014, to U.S. $10 million/year and must increase further to U.S. $44 million (a six-fold increase) in the years 2015 – 2020. These targets need to be met to ensure a minimum of candidate products are moving through the research pipeline into late stage testing for effectiveness.
Just as we use a combination of drugs to treat individuals living with HIV, we need a combination approach to prevention. That approach should include male and female condoms, sterile syringes, and access to treatment as well as new interventions like PrEP, topical microbicides, and vaccines. Adequate funding must continue for all of the methods we currently have, and it must continue for the new strategies that are still being developed as well.
In a global context where millions of individuals do not have access to life saving medications, it is imperative that funding provided for PrEP accessibility not compete with funding for treatment. Treatment funding has not kept pace with the need.
IRMA congratulates the trial sponsors, scientific collaborators and partners who conducted this landmark trial, with special thanks to the 2,499 participants in the study who volunteered so much of their time and energy. Their extraordinary contribution to HIV prevention science brings us another step closer to a day without AIDS, and for that we are supremely grateful.
Your field guide to gay men's health. The blog is no longer active, but is still available to use as an information resource.
Subscribe to:
Post Comments (Atom)
select key words
2007 National HIV Prevention Conference
2009 National LGBTI Health Summit
2011 LGBTI Health Summit
2012 Gay Men's Health Summit
2012 International AIDS Conference
abstinence only
ACT Up
activism
advocacy
Africa
african-american
aging issues
AIDS
AIDS Foundation of Chicago
anal cancer
anal carcinoma
anal health
anal sex
andrew's anus
athlete
ball scene
bareback porn
barebacking
bathhouses
bears
big bold and beautiful
Bisexual
Bisexual Health Summit
bisexuality
black gay men
black msm
blood ban
blood donor
body image
bottom
Brian Mustanski
BUTT
Center on Halsted
Charles Stephens
Chicago
Chicago Black Gay Men's Caucus
Chicago Task Force on LGBT Substance Use and Abuse
Chris Bartlett
chubby chaser
circumcision
civil rights
civil union
Coaching with Jake
communication
community organizing
condoms
Congress
crystal meth
dating
dating and mating with alan irgang
David Halperin
David Munar
depression
disclosure
discrimination
domestic violence
don't ask don't tell
douche
downlow
Dr. James Holsinger
Dr. Jesus Ramirez-Valles
Dr. Rafael Diaz
Dr. Ron Stall
drag queen
Ed Negron
emotional health
ENDA
Eric Rofes
exercise
Feast of Fun
Feel the love...
female condom
fitness
Friday is for Faeries
FTM
gay culture
gay identity
gay latino
gay male sex
gay marriage
gay men
gay men of color
gay men's health
Gay Men's Health Summit 2010
gay pride
gay rights
gay rugby
gay sex
gay youth
gender
harm reduction
hate crime
HCV
health care
health care reform
health insurance
hepatitis C
HIV
HIV care
HIV drugs
HIV negative
HIV positive
HIV prevention
HIV stigma
HIV strategic plan
HIV testing
hiv vaccine
HIV/AIDS
homophobia
homosexuality
hottie
hotties
how are you healthy?
Howard Brown Health Center
HPV
human rights
humor
hunk
Illinois
IML
immigration
International AIDS Conference
international mr. leather
internet
intimacy
IRMA
Jim Pickett
leather community
leathersex
Leon Liberman
LGBT
LGBT adoption
LGBT culture
LGBT health
LGBT rights
LGBT seniors
LGBT youth
LGBTI community
LGBTI culture
LGBTI health
LGBTI rights
LGBTI spirituality
LGV
LifeLube
LifeLube forum
LifeLube poll
LifeLube subscription
lifelube survey
Lorenzo Herrera y Lozano
love
lube
lubricant
Lymphogranuloma Venereum
masturbation
mental health
microbicides
middle
Monday Morning Perk-Up
MRSA
MSM
music
National AIDS Strategy
National Gay Men's Health Summit
negotiated safety
nutrition
One Fey's Tale
oral sex
Peter Pointers
physical health
Pistol Pete
pleasure
PnP
podcast
policy
politics
poppers
porn
post-exposure prophylaxis
PrEP
President Barack Obama
Presidential Campaign
prevention
Project CRYSP
prostate
prostate cancer
public health
public sex venues
queer identity
racism
Radical Faerie
recovery
rectal microbicides
relationships
religion
research
safe sex
semen
Senator Barack Obama
sero-adaptation
sero-sorting
seroguessing
sex
sexual abuse
sexual addiction
sexual health
sexual orientation
Sister Glo
Sisters of Perpetual Indulgence
smoking
social marketing
spirituality
STD
stigma
stonewall riots
substance abuse treatment
substance use
suicide
super-bug
superinfection
Susan Kingston
Swiss declaration
syphilis
Ted Kerr
Test Positive Aware Network
testicle self-examination
testicular cancer
testing
The "Work-In"
The 2009 Gay Men's Health Agenda
Tony Valenzuela
top
Trans and Intersex Association
trans group blog
Trans Gynecology Access Program
transgender
transgender day of remembrance
transgendered
transmen
transphobia
transsexual
Trevor Hoppe
universal health care
unsafe sex
vaccines
video
violence
viral load
Who's That Queer
Woof Wednesday
writers
yoga
You Tube
youtube
This is the first step in preventing the spread of HIV! The next step would be Microbicide's, the next would be a cure to HIV and then we all win!
ReplyDeleteMoving forward pushing on Victory is near!!!